| Nov 13 |
CervoMed Announces Key Senior Leadership Appointments
|
| Nov 12 |
CervoMed GAAP EPS of -$0.55 misses by $0.17, revenue of $1.94M misses by $0.3M
|
| Nov 12 |
CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
|
| Nov 8 |
CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup
|
| Nov 4 |
CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)
|
| Oct 29 |
CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference
|
| Oct 15 |
CervoMed Announces Last Patient Last Visit in Phase 2b RewinD-LB Trial of Neflamapimod for the Treatment of Early-Stage Dementia with Lewy Bodies (DLB)
|
| Oct 4 |
CervoMed Ends $20 Million Stock Sales Agreement with BTIG
|
| Oct 3 |
CervoMed files for $250M mixed securities shelf
|
| Oct 2 |
CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference
|
